<![CDATA[Medical Press Releases - 2026]]> https://www.medicalpressreleases.com/press-releases/ Fri, 17 Apr 2026 13:19:31 +0000 MyBB <![CDATA[President launches TrumpRx.gov website offering Americans discounted prescription dru]]> https://www.medicalpressreleases.com/press-releases/showthread.php?tid=6 Fri, 06 Feb 2026 13:43:26 +0000 jasongeek]]> https://www.medicalpressreleases.com/press-releases/showthread.php?tid=6 Trump slashes cost of medications through deals with 16 major pharmaceutical companies
By Emma Bussey
Published February 5, 2026 9:42pm EST

President Donald Trump unveiled TrumpRx.gov, a new government-backed website aimed at giving Americans access to discounted prescription drugs.

Speaking at the website launch Thursday evening at the White House, Trump argued that Americans have long paid far more for prescription drugs than consumers in other countries and called the price differences unprecedented.

"Americans have long been paying the highest drug prices anywhere in the world, while other countries often paid pennies on the dollar for the exact same drugs," Trump said. "We were essentially subsidizing the entire world by hundreds of billions of dollars every year."

He added that despite accounting for a small share of the global population, Americans bear a disproportionate share of drug costs.

"The United States is just 4% of the world’s population and consumes only 13% of all prescription drugs," he said before confirming new agreements would change that dynamic.

"Under the agreements my administration has negotiated, the United States will pay the lowest price paid by any other country," he said. "We’re taking the lowest price anywhere in the world. That’s the price you’re going to be paying," Trump added.

"They’re going way down for the United States — by differences of as much as 300, 400, 500, even 600%" Trump said. "In some cases, even more."

Trump announced the website at a White House event alongside Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz and National Design Studio Director Joe Gebbia, the Airbnb co-founder advising the administration on digital design and user experience.

The initiative follows agreements between the Trump administration and 16 of the world’s largest pharmaceutical companies under so-called "most-favored-nation" pricing deals.

"All of these discounts and more will be available directly to consumers starting today at TrumpRx.gov," Trump said, adding that 16 of the 17 largest pharmaceutical companies have signed on, with the remaining company expected to join.

In exchange for exemptions from U.S. tariffs, participating drugmakers agreed to lower prices for the federal Medicaid program and extend those reduced prices to cash-paying consumers through TrumpRx.

Among the participating companies are Eli Lilly and Novo Nordisk, which agreed to cut prices on popular GLP-1 weight-loss drugs.

The administration said the agreements are expected to reduce monthly costs for Americans to an average range of $149 to $350.

The administration highlighted price reductions across a range of medications, including inhalers, HIV treatments, diabetes drugs and IVF medications.

Trump cited reductions in weight-loss drugs and inhalers, as well as fertility treatments.

"Novo Nordisk will be slashing the price of Wegovy from more than $1,300 to $199," Trump said. "AstraZeneca is slashing the price of a common inhaler from $458 to $51."

"We’re also delivering historic discounts for couples struggling with infertility," he added, saying manufacturers would dramatically cut the cost of commonly used IVF drugs, including Gonal-F.

The TrumpRx.gov displays discounted prescription drugs, showing users the percentage savings off the original price and generating a coupon for each medication.

Consumers can print the coupon or save it to a mobile wallet and present it at participating pharmacies to receive the discount at checkout. For specialty drugs, the site directs users to mail-order pharmacies that can deliver medications directly to their homes.

According to administration officials, purchases made through the website will generally not count toward insurance deductibles.

https://www.foxbusiness.com/politics/pre...s-historic]]> Trump slashes cost of medications through deals with 16 major pharmaceutical companies
By Emma Bussey
Published February 5, 2026 9:42pm EST

President Donald Trump unveiled TrumpRx.gov, a new government-backed website aimed at giving Americans access to discounted prescription drugs.

Speaking at the website launch Thursday evening at the White House, Trump argued that Americans have long paid far more for prescription drugs than consumers in other countries and called the price differences unprecedented.

"Americans have long been paying the highest drug prices anywhere in the world, while other countries often paid pennies on the dollar for the exact same drugs," Trump said. "We were essentially subsidizing the entire world by hundreds of billions of dollars every year."

He added that despite accounting for a small share of the global population, Americans bear a disproportionate share of drug costs.

"The United States is just 4% of the world’s population and consumes only 13% of all prescription drugs," he said before confirming new agreements would change that dynamic.

"Under the agreements my administration has negotiated, the United States will pay the lowest price paid by any other country," he said. "We’re taking the lowest price anywhere in the world. That’s the price you’re going to be paying," Trump added.

"They’re going way down for the United States — by differences of as much as 300, 400, 500, even 600%" Trump said. "In some cases, even more."

Trump announced the website at a White House event alongside Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz and National Design Studio Director Joe Gebbia, the Airbnb co-founder advising the administration on digital design and user experience.

The initiative follows agreements between the Trump administration and 16 of the world’s largest pharmaceutical companies under so-called "most-favored-nation" pricing deals.

"All of these discounts and more will be available directly to consumers starting today at TrumpRx.gov," Trump said, adding that 16 of the 17 largest pharmaceutical companies have signed on, with the remaining company expected to join.

In exchange for exemptions from U.S. tariffs, participating drugmakers agreed to lower prices for the federal Medicaid program and extend those reduced prices to cash-paying consumers through TrumpRx.

Among the participating companies are Eli Lilly and Novo Nordisk, which agreed to cut prices on popular GLP-1 weight-loss drugs.

The administration said the agreements are expected to reduce monthly costs for Americans to an average range of $149 to $350.

The administration highlighted price reductions across a range of medications, including inhalers, HIV treatments, diabetes drugs and IVF medications.

Trump cited reductions in weight-loss drugs and inhalers, as well as fertility treatments.

"Novo Nordisk will be slashing the price of Wegovy from more than $1,300 to $199," Trump said. "AstraZeneca is slashing the price of a common inhaler from $458 to $51."

"We’re also delivering historic discounts for couples struggling with infertility," he added, saying manufacturers would dramatically cut the cost of commonly used IVF drugs, including Gonal-F.

The TrumpRx.gov displays discounted prescription drugs, showing users the percentage savings off the original price and generating a coupon for each medication.

Consumers can print the coupon or save it to a mobile wallet and present it at participating pharmacies to receive the discount at checkout. For specialty drugs, the site directs users to mail-order pharmacies that can deliver medications directly to their homes.

According to administration officials, purchases made through the website will generally not count toward insurance deductibles.

https://www.foxbusiness.com/politics/pre...s-historic]]> <![CDATA[The Vault Organelle: From Clinical Obstacle to Nanotechnology Breakthrough]]> https://www.medicalpressreleases.com/press-releases/showthread.php?tid=5 Thu, 05 Feb 2026 02:47:16 +0000 jasongeek]]> https://www.medicalpressreleases.com/press-releases/showthread.php?tid=5 The Vault Organelle: From Clinical Obstacle to Nanotechnology Breakthrough
Introduction
Vaults are massive ribonucleoprotein (RNP) complexes found in almost all eukaryotic cells. Since their discovery at UCLA in 1986, these barrel-shaped organelles have transitioned from mysterious cellular structures to key targets in oncology and bioengineering [Wikipedia].
I. Molecular Mechanisms of Chemotherapy Resistance
The strongest clinical link for vaults is their role in Multidrug Resistance (MDR). While they do not act as traditional membrane pumps (like P-glycoprotein), they facilitate resistance through three primary specialized mechanisms [PMC]:
  • []Nucleocytoplasmic Transport & Shuttling: Vaults are often localized near nuclear pore complexes. They are believed to "shuttle" DNA-damaging chemotherapeutics (e.g., doxorubicin) out of the nucleus and into the cytoplasm, preventing the drugs from reaching their genomic targets [ScienceDirect].[]Drug Sequestration (Cellular "Drug Depots"): Their massive hollow interior (approximately 50,000,000 ų) allows them to sequester toxins. In resistant cancer cells, vault synthesis can increase up to 15-fold, effectively acting as "sponges" that soak up drugs and store them in non-lethal compartments like lysosomes [PubMed].[]Regulatory RNA (svRNAb): Vault RNA can be processed into small RNAs (svRNAs) that function like microRNAs. One specific fragment, svRNAb, has been shown to downregulate CYP3A4, a critical enzyme in drug metabolism, thereby altering how the body processes chemotherapy [PubMed].[]Survival Signaling: The Major Vault Protein (MVP) modulates pro-survival pathways such as PI3K/AKT and MAPK, helping cancer cells evade apoptosis (programmed cell death) even under high chemical stress [MDPI].

II. Vaults in Nanotechnology and Targeted Therapy
The very structure that makes vaults a nuisance in cancer treatment makes them an ideal nanodelivery platform for modern medicine [UCLA CNSI].
[indent]
1. Engineered Nanocapsules:
Because MVP self-assembles into a stable shell, researchers use insect cells to mass-produce recombinant vaults. These can be "pre-loaded" with:
  • []Hydrophobic drugs (like All-trans Retinoic Acid) that are otherwise difficult to dissolve in the blood [PMC].[]Proteins and enzymes that need protection from degradation by the immune system.

2. Immunotherapy (The CCL21 Breakthrough):
One of the most promising applications is the CCL21-vault. By packaging the chemokine CCL21 inside a vault, scientists can "wake up" the immune system. When injected into a tumor, the vaults release CCL21 to recruit T-cells and dendritic cells to attack the cancer [UCLA Health].
3. Targeted "Off-the-Shelf" Vectors:
Unlike viral vectors, vaults are naturally occurring in humans and are non-immunogenic. Engineers can attach Cell Penetrating Peptides (CPPs) or antibodies to the vault exterior, allowing them to "home in" on specific tumor markers or cross the blood-brain barrier [PMC].
[/indent]
Summary Table: Clinical Profiles
Code:
+-------------------+----------------------------+----------------------------+
| Component | Pathological Role (MDR) | Nanotech Application |
+-------------------+----------------------------+----------------------------+
| MVP Shell | Drug sequestration/shuttle | Biocompatible nanocarrier |
| Vault RNA (vRNA) | Gene silencing/metabolism | Gene therapy delivery |
| VPARP/TEP1 | DNA repair/Telomere mnt. | Enzymatic "cargo" stabilization|
+-------------------+----------------------------+----------------------------+

References for further study:
  1. []Vault Particles in Cancer Progression & MDR - PMC[]MVP and Apoptosis Resistance - Nature
  2. A Novel Nanofrontier in Drug Delivery - Drug Development & Delivery
]]> The Vault Organelle: From Clinical Obstacle to Nanotechnology Breakthrough
Introduction
Vaults are massive ribonucleoprotein (RNP) complexes found in almost all eukaryotic cells. Since their discovery at UCLA in 1986, these barrel-shaped organelles have transitioned from mysterious cellular structures to key targets in oncology and bioengineering [Wikipedia].
I. Molecular Mechanisms of Chemotherapy Resistance
The strongest clinical link for vaults is their role in Multidrug Resistance (MDR). While they do not act as traditional membrane pumps (like P-glycoprotein), they facilitate resistance through three primary specialized mechanisms [PMC]:
  • []Nucleocytoplasmic Transport & Shuttling: Vaults are often localized near nuclear pore complexes. They are believed to "shuttle" DNA-damaging chemotherapeutics (e.g., doxorubicin) out of the nucleus and into the cytoplasm, preventing the drugs from reaching their genomic targets [ScienceDirect].[]Drug Sequestration (Cellular "Drug Depots"): Their massive hollow interior (approximately 50,000,000 ų) allows them to sequester toxins. In resistant cancer cells, vault synthesis can increase up to 15-fold, effectively acting as "sponges" that soak up drugs and store them in non-lethal compartments like lysosomes [PubMed].[]Regulatory RNA (svRNAb): Vault RNA can be processed into small RNAs (svRNAs) that function like microRNAs. One specific fragment, svRNAb, has been shown to downregulate CYP3A4, a critical enzyme in drug metabolism, thereby altering how the body processes chemotherapy [PubMed].[]Survival Signaling: The Major Vault Protein (MVP) modulates pro-survival pathways such as PI3K/AKT and MAPK, helping cancer cells evade apoptosis (programmed cell death) even under high chemical stress [MDPI].

II. Vaults in Nanotechnology and Targeted Therapy
The very structure that makes vaults a nuisance in cancer treatment makes them an ideal nanodelivery platform for modern medicine [UCLA CNSI].
[indent]
1. Engineered Nanocapsules:
Because MVP self-assembles into a stable shell, researchers use insect cells to mass-produce recombinant vaults. These can be "pre-loaded" with:
  • []Hydrophobic drugs (like All-trans Retinoic Acid) that are otherwise difficult to dissolve in the blood [PMC].[]Proteins and enzymes that need protection from degradation by the immune system.

2. Immunotherapy (The CCL21 Breakthrough):
One of the most promising applications is the CCL21-vault. By packaging the chemokine CCL21 inside a vault, scientists can "wake up" the immune system. When injected into a tumor, the vaults release CCL21 to recruit T-cells and dendritic cells to attack the cancer [UCLA Health].
3. Targeted "Off-the-Shelf" Vectors:
Unlike viral vectors, vaults are naturally occurring in humans and are non-immunogenic. Engineers can attach Cell Penetrating Peptides (CPPs) or antibodies to the vault exterior, allowing them to "home in" on specific tumor markers or cross the blood-brain barrier [PMC].
[/indent]
Summary Table: Clinical Profiles
Code:
+-------------------+----------------------------+----------------------------+
| Component | Pathological Role (MDR) | Nanotech Application |
+-------------------+----------------------------+----------------------------+
| MVP Shell | Drug sequestration/shuttle | Biocompatible nanocarrier |
| Vault RNA (vRNA) | Gene silencing/metabolism | Gene therapy delivery |
| VPARP/TEP1 | DNA repair/Telomere mnt. | Enzymatic "cargo" stabilization|
+-------------------+----------------------------+----------------------------+

References for further study:
  1. []Vault Particles in Cancer Progression & MDR - PMC[]MVP and Apoptosis Resistance - Nature
  2. A Novel Nanofrontier in Drug Delivery - Drug Development & Delivery
]]>